WO2023051814A1 - 吡咯并苯并二氮杂卓类衍生物及其偶联物、其制备方法及其应用 - Google Patents
吡咯并苯并二氮杂卓类衍生物及其偶联物、其制备方法及其应用 Download PDFInfo
- Publication number
- WO2023051814A1 WO2023051814A1 PCT/CN2022/123462 CN2022123462W WO2023051814A1 WO 2023051814 A1 WO2023051814 A1 WO 2023051814A1 CN 2022123462 W CN2022123462 W CN 2022123462W WO 2023051814 A1 WO2023051814 A1 WO 2023051814A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- group
- antibody
- cycloalkyl
- pharmaceutically acceptable
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 94
- 229940049595 antibody-drug conjugate Drugs 0.000 claims abstract description 73
- 239000000611 antibody drug conjugate Substances 0.000 claims abstract description 69
- 239000003814 drug Substances 0.000 claims abstract description 54
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 292
- -1 amino, hydroxyl Chemical group 0.000 claims description 146
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 135
- 235000000346 sugar Nutrition 0.000 claims description 113
- 125000001424 substituent group Chemical group 0.000 claims description 109
- 125000000623 heterocyclic group Chemical group 0.000 claims description 108
- 150000003839 salts Chemical class 0.000 claims description 99
- 125000004429 atom Chemical group 0.000 claims description 81
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 80
- 229910052757 nitrogen Inorganic materials 0.000 claims description 79
- 125000003118 aryl group Chemical group 0.000 claims description 73
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 68
- 125000003545 alkoxy group Chemical group 0.000 claims description 65
- 229910052736 halogen Inorganic materials 0.000 claims description 61
- 150000002367 halogens Chemical class 0.000 claims description 61
- 125000001072 heteroaryl group Chemical group 0.000 claims description 57
- 229940079593 drug Drugs 0.000 claims description 50
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 38
- 125000004043 oxo group Chemical group O=* 0.000 claims description 37
- 230000027455 binding Effects 0.000 claims description 36
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 35
- 125000002947 alkylene group Chemical group 0.000 claims description 35
- 229910052717 sulfur Inorganic materials 0.000 claims description 34
- 229910052799 carbon Inorganic materials 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 31
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 31
- 125000005647 linker group Chemical group 0.000 claims description 30
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 25
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
- 125000004434 sulfur atom Chemical group 0.000 claims description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 125000001188 haloalkyl group Chemical group 0.000 claims description 18
- 238000010348 incorporation Methods 0.000 claims description 18
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 17
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 15
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 13
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 238000011068 loading method Methods 0.000 claims description 11
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 9
- 125000003277 amino group Chemical group 0.000 claims description 9
- 125000004011 3 membered carbocyclic group Chemical group 0.000 claims description 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 229960002173 citrulline Drugs 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 6
- 235000013477 citrulline Nutrition 0.000 claims description 6
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 235000004400 serine Nutrition 0.000 claims description 6
- 229960001153 serine Drugs 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 5
- 150000001408 amides Chemical group 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 229960002989 glutamic acid Drugs 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010025598 Malignant hydatidiform mole Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- 229960005261 aspartic acid Drugs 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 150000008134 glucuronides Chemical class 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000008824 placental choriocarcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229930182480 glucuronide Natural products 0.000 claims description 3
- 150000002337 glycosamines Chemical group 0.000 claims description 3
- MALIONKMKPITBV-UHFFFAOYSA-N 2-(3-chloro-4-hydroxyphenyl)-n-[2-(4-sulfamoylphenyl)ethyl]acetamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CCNC(=O)CC1=CC=C(O)C(Cl)=C1 MALIONKMKPITBV-UHFFFAOYSA-N 0.000 claims description 2
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 claims description 2
- 230000002494 anti-cea effect Effects 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 239000000562 conjugate Substances 0.000 abstract description 5
- 201000011510 cancer Diseases 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 description 283
- 239000000243 solution Substances 0.000 description 272
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 237
- 239000000047 product Substances 0.000 description 211
- 238000004949 mass spectrometry Methods 0.000 description 193
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 189
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 170
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 132
- 230000002829 reductive effect Effects 0.000 description 131
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 116
- 125000005605 benzo group Chemical group 0.000 description 104
- 229950011148 cyclopropane Drugs 0.000 description 102
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 100
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 96
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 94
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 87
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 85
- 239000012074 organic phase Substances 0.000 description 83
- 239000003480 eluent Substances 0.000 description 65
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 63
- 238000003756 stirring Methods 0.000 description 60
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 57
- 238000005481 NMR spectroscopy Methods 0.000 description 56
- 125000005336 allyloxy group Chemical group 0.000 description 55
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 47
- 238000000034 method Methods 0.000 description 46
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- 229910052805 deuterium Inorganic materials 0.000 description 42
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 42
- 238000004809 thin layer chromatography Methods 0.000 description 42
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 40
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 239000000203 mixture Substances 0.000 description 39
- 239000000706 filtrate Substances 0.000 description 36
- 239000002994 raw material Substances 0.000 description 36
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 35
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 35
- 125000006413 ring segment Chemical group 0.000 description 34
- BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 34
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 33
- 239000007858 starting material Substances 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- 238000010898 silica gel chromatography Methods 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 239000005457 ice water Substances 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 25
- 238000000746 purification Methods 0.000 description 25
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 24
- 239000008346 aqueous phase Substances 0.000 description 23
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 22
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- 235000008504 concentrate Nutrition 0.000 description 21
- 239000012141 concentrate Substances 0.000 description 21
- 239000012299 nitrogen atmosphere Substances 0.000 description 21
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 21
- 229910000027 potassium carbonate Inorganic materials 0.000 description 21
- QPPLBCQXWDBQFS-UHFFFAOYSA-N 1,4-diazepan-5-one Chemical compound O=C1CCNCCN1 QPPLBCQXWDBQFS-UHFFFAOYSA-N 0.000 description 20
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 20
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 20
- 238000001914 filtration Methods 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- 238000004128 high performance liquid chromatography Methods 0.000 description 19
- 239000012071 phase Substances 0.000 description 19
- 229920006395 saturated elastomer Polymers 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 18
- 239000001257 hydrogen Substances 0.000 description 17
- LSKYURVDOIDSCG-UHFFFAOYSA-N [4-(4-methylpiperazin-1-yl)phenyl]boronic acid Chemical compound C1CN(C)CCN1C1=CC=C(B(O)O)C=C1 LSKYURVDOIDSCG-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 238000010791 quenching Methods 0.000 description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- 235000019270 ammonium chloride Nutrition 0.000 description 14
- 238000001816 cooling Methods 0.000 description 14
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 125000003367 polycyclic group Chemical group 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 239000011593 sulfur Substances 0.000 description 12
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 11
- NBFABZHUOJWSDM-UHFFFAOYSA-N 5h-pyrrolo[1,2-a][1,4]diazepine Chemical compound C1C=CN=CC2=CC=CN12 NBFABZHUOJWSDM-UHFFFAOYSA-N 0.000 description 11
- 239000011259 mixed solution Substances 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 125000002619 bicyclic group Chemical group 0.000 description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000012362 glacial acetic acid Substances 0.000 description 9
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 8
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 8
- 102000051366 Glycosyltransferases Human genes 0.000 description 8
- 108700023372 Glycosyltransferases Proteins 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001294 propane Substances 0.000 description 8
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 125000004438 haloalkoxy group Chemical group 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- CAEWJEXPFKNBQL-UHFFFAOYSA-N prop-2-enyl carbonochloridate Chemical compound ClC(=O)OCC=C CAEWJEXPFKNBQL-UHFFFAOYSA-N 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 150000003852 triazoles Chemical group 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical class [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 6
- 241000662429 Fenerbahce Species 0.000 description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 150000003457 sulfones Chemical class 0.000 description 6
- 150000003462 sulfoxides Chemical class 0.000 description 6
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 5
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 5
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 5
- 239000001099 ammonium carbonate Substances 0.000 description 5
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 5
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000007634 remodeling Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 239000005909 Kieselgur Substances 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 108091022873 acetoacetate decarboxylase Proteins 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 4
- 239000007822 coupling agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- XYURSCOGYWBRDR-UHFFFAOYSA-N n-diazoimidazole-1-sulfonamide;hydrochloride Chemical compound Cl.[N-]=[N+]=NS(=O)(=O)N1C=CN=C1 XYURSCOGYWBRDR-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- SKUDUPVJZBDKND-UHFFFAOYSA-N [4-(cyclopropylmethylsulfanyl)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1SCC1CC1 SKUDUPVJZBDKND-UHFFFAOYSA-N 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- KMJYGLJORYOCJF-OABTZWTBSA-L disodium;5-acetamido-2-[[6-[5-acetamido-6-[2-[[6-[5-acetamido-6-[5-acetamido-6-[[(3s)-4-[[(2s)-6-amino-1-[[(1s,2r)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]amino]-3-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propano Chemical compound [Na+].[Na+].OC1C(NC(C)=O)C(NC(=O)C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)OC(CO)C1OC1C(NC(C)=O)C(O)C(OC2C(C(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(OC4C(C(O)C(O)C(COC5(OC(C(NC(C)=O)C(O)C5)[C@H](O)[C@H](O)CO)C([O-])=O)O4)O)C(CO)O3)NC(C)=O)C(O)C(COC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(OC4C(C(O)C(O)C(COC5(OC(C(NC(C)=O)C(O)C5)[C@H](O)[C@H](O)CO)C([O-])=O)O4)O)C(CO)O3)NC(C)=O)O2)O)C(CO)O1 KMJYGLJORYOCJF-OABTZWTBSA-L 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 3
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 2
- YSGPYVWACGYQDJ-RXMQYKEDSA-N (4s)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde Chemical compound CC1(C)OC[C@@H](C=O)O1 YSGPYVWACGYQDJ-RXMQYKEDSA-N 0.000 description 2
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 2
- RVWUHFFPEOKYLB-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxidopiperidin-1-ium Chemical compound CC1(C)CCCC(C)(C)[NH+]1[O-] RVWUHFFPEOKYLB-UHFFFAOYSA-N 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 2
- NNWFSRBWMOZDAK-UHFFFAOYSA-N 2-[2-(carboxymethyl)-3-iodophenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(I)=C1CC(O)=O NNWFSRBWMOZDAK-UHFFFAOYSA-N 0.000 description 2
- FPVCVHVTMPCZTH-UHFFFAOYSA-N 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethanamine Chemical compound NCCOCCOCCOCCN=[N+]=[N-] FPVCVHVTMPCZTH-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 101001106322 Homo sapiens Rho GTPase-activating protein 7 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 101710096655 Probable acetoacetate decarboxylase 1 Proteins 0.000 description 2
- 102100021446 Rho GTPase-activating protein 7 Human genes 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- PWQLZSHJRGGLBC-UHFFFAOYSA-N acetonitrile;carbon dioxide Chemical compound CC#N.O=C=O PWQLZSHJRGGLBC-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical group 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- PSHMSSXLYVAENJ-UHFFFAOYSA-N dilithium;[oxido(oxoboranyloxy)boranyl]oxy-oxoboranyloxyborinate Chemical compound [Li+].[Li+].O=BOB([O-])OB([O-])OB=O PSHMSSXLYVAENJ-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229960004275 glycolic acid Drugs 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- XTVMZKCCFLOJBL-UHFFFAOYSA-N (4-pyrazol-1-ylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1N1N=CC=C1 XTVMZKCCFLOJBL-UHFFFAOYSA-N 0.000 description 1
- YSGPYVWACGYQDJ-YFKPBYRVSA-N (4r)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde Chemical compound CC1(C)OC[C@H](C=O)O1 YSGPYVWACGYQDJ-YFKPBYRVSA-N 0.000 description 1
- RXNPEQZHMGFNAY-GEALJGNFSA-N (5R)-4-[(1S,6R)-5-[(2S)-2-(4-chlorophenyl)-3-(propan-2-ylamino)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@H]1CC(=O)NC2=C1C(=NC=N2)N3CCN([C@H]4[C@@H]3C4)C(=O)[C@H](CNC(C)C)C5=CC=C(C=C5)Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 description 1
- OMRPLUKQNWNZAV-CONSDPRKSA-N (6as)-3-[3-[[(6as)-2-methoxy-8-(4-methoxyphenyl)-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-8-(4-aminophenyl)-2-methoxy-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound C1=CC(OC)=CC=C1C1=CN2C(=O)C3=CC(OC)=C(OCCCOC=4C(=CC=5C(=O)N6C=C(C[C@H]6C=NC=5C=4)C=4C=CC(N)=CC=4)OC)C=C3N=C[C@@H]2C1 OMRPLUKQNWNZAV-CONSDPRKSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- ZFNNBIMQDHBELV-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-cyclohexylpropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;dihydrochloride Chemical compound Cl.Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C(C=1)=CC=CC=1OCCCC1CCCCC1 ZFNNBIMQDHBELV-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- FOZVXADQAHVUSV-UHFFFAOYSA-N 1-bromo-2-(2-bromoethoxy)ethane Chemical compound BrCCOCCBr FOZVXADQAHVUSV-UHFFFAOYSA-N 0.000 description 1
- DGEUSHXVDCWKFE-UHFFFAOYSA-N 1-bromo-4-(cyclopropylmethylsulfanyl)benzene Chemical compound C1=CC(Br)=CC=C1SCC1CC1 DGEUSHXVDCWKFE-UHFFFAOYSA-N 0.000 description 1
- BIVPXDHUZDKZKC-UHFFFAOYSA-N 1-bromo-4-cyclopropylsulfanylbenzene Chemical compound C1=CC(Br)=CC=C1SC1CC1 BIVPXDHUZDKZKC-UHFFFAOYSA-N 0.000 description 1
- HAJJQQQLAXFDAW-UHFFFAOYSA-N 1-cyclopropyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine Chemical compound CC1(OB(C2=CC=C(C3CCN(CC3)C3CC3)C=C2)OC1(C)C)C HAJJQQQLAXFDAW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- PHXZOQVBYCJBHO-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methoxy]ethanol Chemical compound COC1=CC=C(COCCO)C=C1 PHXZOQVBYCJBHO-UHFFFAOYSA-N 0.000 description 1
- ZHWGWSYNZIZTFL-UHFFFAOYSA-N 2-[2-(2-azidoethoxy)ethoxy]ethanamine Chemical compound NCCOCCOCCN=[N+]=[N-] ZHWGWSYNZIZTFL-UHFFFAOYSA-N 0.000 description 1
- PTOJCKLTCKYNFG-UHFFFAOYSA-N 2-[2-(2-azidoethoxy)ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCOCCOCCN=[N+]=[N-])C=C1 PTOJCKLTCKYNFG-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- BSULWPSUVMOMAN-UHFFFAOYSA-N 2-azidoethanol Chemical compound OCCN=[N+]=[N-] BSULWPSUVMOMAN-UHFFFAOYSA-N 0.000 description 1
- PTDNHYVEBIHJBK-UHFFFAOYSA-M 2-chloro-1,3-dimethylimidazol-1-ium;chloride Chemical compound [Cl-].CN1C=C[N+](C)=C1Cl PTDNHYVEBIHJBK-UHFFFAOYSA-M 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- KYWHOZQCDQJDRN-UHFFFAOYSA-N 3,5-bis(chloromethyl)pyridine;hydrochloride Chemical compound Cl.ClCC1=CN=CC(CCl)=C1 KYWHOZQCDQJDRN-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- DMLXOYKSKYTGKQ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-[4-(oxan-4-yl)phenyl]-1,3,2-dioxaborolane Chemical group O1C(C)(C)C(C)(C)OB1C1=CC=C(C2CCOCC2)C=C1 DMLXOYKSKYTGKQ-UHFFFAOYSA-N 0.000 description 1
- KKLCYBZPQDOFQK-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC=C1 KKLCYBZPQDOFQK-UHFFFAOYSA-N 0.000 description 1
- AFZIRBOYYNKYFJ-UHFFFAOYSA-N 4-pyridin-2-ylsulfanylpentanoic acid Chemical compound OC(=O)CCC(C)SC1=CC=CC=N1 AFZIRBOYYNKYFJ-UHFFFAOYSA-N 0.000 description 1
- ZREAUMPQOSIHOV-UHFFFAOYSA-N 5-methoxy-2-nitro-4-tri(propan-2-yl)silyloxybenzoic acid Chemical compound COC1=CC(C(O)=O)=C([N+]([O-])=O)C=C1O[Si](C(C)C)(C(C)C)C(C)C ZREAUMPQOSIHOV-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 101100396152 Arabidopsis thaliana IAA19 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229930182476 C-glycoside Natural products 0.000 description 1
- 150000000700 C-glycosides Chemical class 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- BBXUNNIXUWUZAY-NSHDSACASA-N CC(C)(C)[Si](C)(C)OC[C@@H]1CC2(CC2)CN1 Chemical compound CC(C)(C)[Si](C)(C)OC[C@@H]1CC2(CC2)CN1 BBXUNNIXUWUZAY-NSHDSACASA-N 0.000 description 1
- ANSSFBUULKCRAA-SNAWJCMRSA-N CCOC(=O)\C=C\C1(COS(C)(=O)=O)CC1 Chemical compound CCOC(=O)\C=C\C1(COS(C)(=O)=O)CC1 ANSSFBUULKCRAA-SNAWJCMRSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 102100039292 Cbp/p300-interacting transactivator 1 Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000012626 DNA minor groove binder Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101000888413 Homo sapiens Cbp/p300-interacting transactivator 1 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100274486 Mus musculus Cited2 gene Proteins 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-methylmorpholine Substances CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- 150000008444 O-glycosides Chemical class 0.000 description 1
- YAZVPPUKECTWAD-UHFFFAOYSA-N OCCOCCCOCCN=[N+]=[N-] Chemical compound OCCOCCCOCCN=[N+]=[N-] YAZVPPUKECTWAD-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000035193 Ring chromosome 10 syndrome Diseases 0.000 description 1
- 229930182475 S-glycoside Natural products 0.000 description 1
- 101150096622 Smr2 gene Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- QTSFFAMXXWSKRY-UHFFFAOYSA-N [4-(triazol-2-yl)phenyl]boronic acid Chemical compound OB(O)c1ccc(cc1)-n1nccn1 QTSFFAMXXWSKRY-UHFFFAOYSA-N 0.000 description 1
- AAELHWDCDSZXGG-UHFFFAOYSA-L [Na+].[Cl+].[Cl-].[Cl-] Chemical class [Na+].[Cl+].[Cl-].[Cl-] AAELHWDCDSZXGG-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- HKVFISRIUUGTIB-UHFFFAOYSA-O azanium;cerium;nitrate Chemical compound [NH4+].[Ce].[O-][N+]([O-])=O HKVFISRIUUGTIB-UHFFFAOYSA-O 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 150000001804 chlorine Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 125000005345 deuteroalkyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- ZORHSASAYVIBLY-CNZKWPKMSA-N methyl (4r)-4-hydroxypyrrolidine-2-carboxylate Chemical compound COC(=O)C1C[C@@H](O)CN1 ZORHSASAYVIBLY-CNZKWPKMSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- HVAMZGADVCBITI-UHFFFAOYSA-M pent-4-enoate Chemical compound [O-]C(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-M 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005494 pyridonyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DVFXLNFDWATPMW-IWOKLKJTSA-N tert-butyldiphenylsilyl Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DVFXLNFDWATPMW-IWOKLKJTSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 description 1
- RIUWBIIVUYSTCN-UHFFFAOYSA-N trilithium borate Chemical compound [Li+].[Li+].[Li+].[O-]B([O-])[O-] RIUWBIIVUYSTCN-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Definitions
- Rx is H or hydroxyl
- R 5 is H, halogen or alkyl
- R 8 is an alkyl group; preferably, R 8 is a C 1-6 alkyl group; more preferably, R 8 is a methyl group;
- R 3 and R 4 form a ring together with the atoms they are connected to; preferably, R 3 and R 4 form a 3-membered carbocyclic ring together with the atoms they are connected to;
- R 7 is an alkyl group; preferably, R 7 is a C 1-6 alkyl group; more preferably, R 7 is a methyl group;
- the wavy line Indicates binding to Asn at position 297 of the Pc heavy chain
- the present disclosure provides a Pc-(sugar chain N297), the structure of which is as follows:
- L d is -NH-R a -CH 2 OC(O)-, -NH-CH 2 OR b -C(O)- or a bond;
- R 20 is alkyl or cycloalkyl
- R 13 is L a' -L b -L c -L d -:
- X' is an alkylene group; preferably, X' is a C 1-6 alkylene group; more preferably, X' is a pentylene group; Y' is an oxygen atom;
- Typical compounds disclosed in this disclosure include, but are not limited to:
- peptide refers to a molecule composed of two or more amino acid molecules connected to each other by peptide bonds.
- the starting material 1i in the ninth step of Example 2-11 was replaced with 4a (54 mg, 0.10 mmol), and the title product 4b (50 mg, yield: 80%) was obtained under the same reaction conditions.
Abstract
Description
实施例编号 | SK-BR-3 | NCI-H23 | MKN45 |
2-1 | 0.07 | 0.02 | 0.02 |
2-2 | 0.05 | 0.02 | 0.09 |
2-3 | 0.20 | 0.05 | 0.49 |
2-4 | 0.71 | 0.34 | 1.45 |
2-5 | 1.84 | 0.41 | 0.91 |
2-6 | 0.24 | 0.03 | 0.06 |
2-7 | 0.08 | 0.04 | 0.07 |
2-9 | 1.25 | 0.23 | 0.19 |
2-10 | 0.63 | 0.2 | 0.61 |
2-11 | 0.32 | 0.11 | 0.69 |
2-13 | 1.64 | 1.42 | 4.35 |
2-16 | 0.36 | 0.18 | 0.26 |
2-21 | 0.28 | 0.12 | 0.57 |
2-22 | 0.26 | 0.08 | 0.17 |
2-26 | 2.12 | 2.98 | 2.42 |
2-27 | 5 | 7.28 | 7.51 |
2-29 | 0.08 | 0.02 | 0.02 |
2-30 | 0.21 | 0.02 | 0.04 |
2-31 | 0.37 | 0.08 | 0.10 |
2-32 | 0.78 | 0.09 | 0.13 |
2-33 | 0.73 | 0.30 | 0.38 |
2-34 | 1.42 | 0.62 | 1.37 |
2-35 | 1.70 | 0.84 | 2.73 |
2-39 | 0.58 | 0.39 | 0.84 |
Claims (37)
- 一种如下式所示抗体-药物偶联物或其可药用的盐:其中,Pc为抗体,该抗体的糖链是未重构的或重构的糖链;L为连接子;Pc通过其氨基酸或糖链与L结合,y为约1至约10的载药量;D如式(D)所示:其中:R 1为H、氧代基、卤素或烷基;R 3为H或烷基;R 4为H或烷基;R 5为H、卤素或烷基;或者R 3和R 4与其所连接的原子一起成环,或R 4和R 5与其所连接的原子一起成环;R 6为H或烷基;R 7为烷基或环烷基;或者R 6和R 7与其所连接的原子一起成环;R 8为烷基或环烷基;R x为H或羟基;X为亚烷基或-(CH 2) m-X 1-(CH 2) n-;X 1为氮原子、氧原子、硫原子、环烷基、杂环基、杂芳基或芳基;所述的环烷基、杂环基、杂芳基或芳基任选被一个或多个取代基所取代,其中每个取代基 独立地选自氨基、羟基、羟烷基、烷基和烷氧基;Y为键、氮原子、氧原子或硫原子;A为烷基、环烷基、杂环基、芳基或杂芳基,所述的环烷基、杂环基、芳基或杂芳基任选被一个或多个取代基所取代,其中每个取代基独立地选自卤素、羟基、羟烷基、烷基、烷氧基、-C(O)R 9、环烷基、环烷基烷基、卤代烷基、芳基和杂环基;R 9为H、烷基和羟烷基;m为1,2或3;n为1,2或3;条件是当X为亚烷基时,1)R 1为氧代基,或2)R x为H,或3)R 4和R 5与其所连接的原子一起成环,或4)R 6和R 7与其所连接的原子一起成环,或5)R 7和/或R 8为环烷基;或6)A不是烷基。
- 根据权利要求1所述的抗体-药物偶联物或其可药用的盐,其中所述R 1为H或氧代基;优选地,R 1为H。
- 根据权利要求1或2所述的抗体-药物偶联物或其可药用的盐,其中所述R 2为H或C 1-6烷基;优选地,R 2为H。
- 根据权利要求1至4中任一项所述的抗体-药物偶联物或其可药用的盐,其中所述R x为羟基。
- 根据权利要求1至5中任一项所述的抗体-药物偶联物或其可药用的盐,其中:R 1为H或烷基;优选地,R 1为H或C 1-6烷基;更优选地,R 1为H;R 3和R 4与其所连接的原子一起成环;优选地,R 3和R 4与其所连接的原子一 起形成3元环烷基;R 5为H;R 6为H;R 7是烷基;优选地,R 7为C 1-6烷基;更优选地,R 7为甲基;R 8是烷基;优选地,R 8为C 1-6烷基;更优选地,R 8为甲基;X为亚烷基;优选地,X为C 1-12亚烷基;更优选地,X为亚戊基;Y选自键、氮原子、氧原子或硫原子;优选地,Y为键或硫原子;更优选地,Y为键;A选自环烷基、杂环基、芳基或杂芳基,所述的环烷基、杂环基、芳基或杂芳基任选被一个或多个取代基所取代,其中每个取代基独立地选自卤素、羟基、羟烷基、烷基、烷氧基、-C(O)R 9、环烷基、环烷基烷基、卤代烷基、芳基和杂环基;优选地,A选自C 3-6环烷基、5至6元杂环基、苯基或5至6元杂芳基,所述的C 3-6环烷基、5至6元杂环基、苯基或5至6元杂芳基任选被一个或多个取代基所取代,其中每个取代基独立地选自C 1-6羟烷基、C 1-6烷基、C 3-6环烷基C 1-6烷基、C 1-6卤代烷基和-C(O)R 9;R 9选自H、烷基和羟烷基;优选地,R 9为C 1-6烷基或C 1-6羟烷基。
- 根据权利要求1至5中任一项所述的抗体-药物偶联物或其可药用的盐,其中:R 1为H或烷基;优选地,R 1为H或C 1-6烷基;更优选地,R 1为H;R 3和R 4与其所连接的原子一起成环;优选地,R 3和R 4与其所连接的原子一起形成3元碳环;R 5为H;R 6为H;R 7是烷基;优选地,R 7为C 1-6烷基;更优选地,R 7为甲基;R 8是烷基;优选地,R 8为C 1-6烷基;更优选地,R 8为甲基;X为-(CH 2) m-X 1-(CH 2) n-;X 1为氧原子、环烷基、杂芳基或芳基;所述的环烷基、杂芳基或芳基任选被一个或多个取代基所取代,其中每个取代基独立地选自氨基、羟基、羟烷基、烷基和烷氧基;优选地,X 1为氧原子、C 3-6环烷基、吡啶基或苯基;所述的C 3-6环烷基或苯基任选被一个或多个氨基或C 1-6烷基所取代;m选自1,2或3;n选自1,2或3。
- 根据权利要求1至5任一项所述的抗体-药物偶联物或其可药用的盐,其中:R 1为H或烷基;优选地,R 1为H或C 1-6烷基;更优选地,R 1为H;R 3和R 4与其所连接的原子一起成环;优选地,R 3和R 4与其所连接的原子一起形成3元碳环;X为亚烷基;优选地,X为C 1-6亚烷基;更优选地,X为亚戊基;R 6为H或烷基;优选地,R 6为H或C 1-6烷基;R 7为烷基或环烷基;优选地,R 7为C 1-6烷基或C 3-6环烷基;或者R 6和R 7与其所连接的原子一起成环;优选地,R 6和R 7与其所连接的原子一起形成4-6元环;R 8为烷基或环烷基;优选地,R 8为C 1-6烷基或C 3-6环烷基;条件是,R 7和R 8不同时为烷基。
- 根据权利要求1至5中任一项所述的抗体-药物偶联物或其可药用的盐,其中R 1为H或烷基;优选地,R 1为H或C 1-6烷基;更优选地,R 1为H;R 3为H;R 4和R 5与其所连接的原子一起成环;优选地,R 4和R 5与其所连接的原子一起形成3元碳环;R 6为H;R 7是烷基;优选地,R 7为C 1-6烷基;更优选地,R 7为甲基;R 8是烷基;优选地,R 8为C 1-6烷基;更优选地,R 8为甲基;X为亚烷基;优选地,X为C 1-12亚烷基;更优选地,X为亚戊基。
- 根据权利要求1至9中任一项所述的抗体-药物偶联物或其可药用的盐,其中L为-L a-L b-L c-L d-,L a选自:L b选自-C(O)-CH 2CH 2-C(O)-、-C(O)-(CH 2CH 2) 2-C(O)-、-C(O)-CH 2CH 2-C(O)-NH-(CH 2CH 2) 2-C(O)-、-C(O)-CH 2CH 2-C(O)-NH-(CH 2CH 2O) 2-CH 2-C(O)-、-C(O)-CH 2CH 2-NH-C(O)-(CH 2CH 2O) 4-CH 2CH 2-C(O)-、-CH 2-OC(O)-和-OC(O)-;L c为由2至7个氨基酸残基构成的肽残基,其中所述氨基酸残基是由苯丙氨酸、丙氨酸、脯氨酸、异亮氨酸、甘氨酸、缬氨酸、赖氨酸、瓜氨酸、丝氨酸、谷氨酸或天冬氨酸所形成的残基,所述氨基酸残基是未被取代的或各自独立地被一个或多个取代基所取代,其中每个取代基独立地选自卤素、羟基、氰基、氨基、C 1-6烷基、卤代C 1-6烷基、C 1-6烷氧基和C 3-7环烷基;L d为-NH-R a-CH 2O-C(O)-、-NH-CH 2O-R b-C(O)-或键;R a为苯基或5-6元杂环基,所述苯基和5-6元杂环基是未被取代的或各自独立地被一个或多个取代基所取代,其中每个取代基独立地选自卤素、氧代基、羟基、氰基、氨基、C 1-6烷基、卤代C 1-6烷基和C 1-6烷氧基;R b为C 1-6烷基或C 3-7环烷基,所述C 1-6烷基和C 3-7环烷基是未被取代的或各自独立地被一个或多个取代基所取代,其中每个取代基独立地选自卤素、氧代基、羟基、氰基、氨基、C 1-6烷基、C 3-7环烷基、5-6元杂环基、卤代C 1-6烷基和C 1-6烷氧基。
- 根据权利要求10所述的抗体-药物偶联物或其可药用的盐,其中L b为-C(O)-CH 2CH 2-C(O)-。
- 根据权利要求10所述的抗体-药物偶联物或其可药用的盐,其中L c为-GGVA-、-VA-、-GGFG-、-GGPI-、-GGVK-和-GGPL-;优选为-GGVA-。
- 根据权利要求10所述的抗体-药物偶联物或其可药用的盐,其中L d为-NH-R a-CH 2O-C(O)-,R a为苯基。
- 根据权利要求1至13中任一项所述的抗体-药物偶联物或其可药用的盐,所述Pc为与肿瘤细胞结合且能被吞入肿瘤细胞内的抗体;优选地,所述Pc选自抗HER2(ErbB2)抗体、抗EGFR抗体、抗B7H3抗体、抗c-Met抗体、抗HER3(ErbB3)抗体、抗HER4(ErbB4)抗体、抗CD20抗体、抗CD22抗体、抗CD30抗体、抗CD33抗体、抗CD44抗体、抗CD56抗体、抗CD70抗体、抗CD73抗体、抗CD105抗体、抗CEA抗体、抗A33抗体、抗Cripto抗体、抗EphA2抗体、抗G250抗体、抗MUCl抗体、抗Lewis Y抗体、抗VEGFR抗体、抗GPNMB抗体、抗Integrin抗体、抗PSMA抗体、抗Tenascin-C抗体、抗Claudin18.2抗体、抗ROR1抗体、抗CD19抗体、抗Trop2抗体、抗CD79b抗体、抗SLC44A4抗体和抗Mesothelin抗体。
- 根据权利要求1至14中任一项所述的抗体-药物偶联物或其可药用的盐,其中所述y为1至8,优选为1至4。
- 根据权利要求1至15中任一项所述的抗体-药物偶联物或其可药用的盐,所述Pc通过其N297糖链与L结合,所述N297糖链结合于Pc重链第297位的Asn。
- 根据权利要求1至16中任一项所述的抗体-药物偶联物或其可药用的盐, 其为如下结构:Pc-(N297糖链)-[L-D]y所述的N297糖链为重构的糖链,结合于Pc重链第297位的Asn;其中y为1至4,优选为1至2;Pc、L、D如权利要求1中所述。
- 根据权利要求1至17中任一项所述的抗体-药物偶联物或其可药用的盐,其中所述的糖链为N297糖链,结构选自如下所述的[N297-(Fuc)SG1]、[N297-(Fuc)SG2]、[N297-(Fuc)SG3]、[N297-(Fuc)SG4]和[N297-(Fuc)SG5]:L(PEG)表示-(CH 2CH 2O)qCH 2CH 2-NH-,右端的氨基表示与N297糖链的β-Man支链的1-3链侧或/和1-6链侧的非还原末端的N-乙酰基神经氨酸的2位羧酸进行酰胺键合;q为0至20,优选为1至10;星号*表示与所述连接子L结合;优选地,所述的糖链结构为:;其中q为2或3。
- 根据权利要求1至17中任一项所述的抗体-药物偶联物或其可药用的盐,其中所述的糖链结构为:P 1、P 2各自独立地选自羟基、*-(CH 2CH 2O)s 1-和*-(CH 2CH 2O)s 2-(CH 2CH 2CH 2O)s 3-(CH 2CH 2O)s 4-,所述的*-(CH 2CH 2O)s 1-和*-(CH 2CH 2O)s 2-(CH 2CH 2CH 2O)s 3-(CH 2CH 2O)s 4-是未被取代的或各自独立地被一个或多个取代基所取代,其中每个取代基独立地选自卤素、C 1-6烷基、C 3-6环烷基和C 1-6烷氧基;星号*表示与所述连接子L结合;s 1选自1-10,优选1-5;s 2选自0-10,优选1-5;s 3选自1-10,优选1-5;s 4选自0-10,优选1-5;条件是,P 1、P 2不同时为羟基或*-(CH 2CH 2O)s 1-;优选地,所述的糖链结构选自:
- [援引加入(细则20.6) 27.12.2022]
根据权利要求1至19中任一项所述的抗体-药物偶联物或其可药用的盐,其选自以下的组:
组1:
组2:
组3:
组4:
组5:
组6:
组7:
组8:
组9:
组10:
组11:
组12:
组13:
组14:
组15:
组16:
和/或
;
组17:
组18:
其中:
y选自1至4,优选为1至2;
所述的N297糖链结构选自:
式中,波浪线 表示与Pc重链第297位的Asn结合,星号*表示与所述连接子L结合;
L(PEG)表示-(CH 2CH 2O)qCH 2CH 2-NH-,q选自0-20,优选自1-10;右端的氨基表示与N297糖链的β-Man支链的1-3链侧或/和1-6链侧的非还原末端的N-乙酰基神经氨酸的2位羧酸进行酰胺键合;
或者,所述的N297糖链结构选自:
式中,波浪线 表示与Pc重链第297位的Asn结合;
P 1、P 2各自独立地选自羟基、*-(CH 2CH 2O)s 1-和*-(CH 2CH 2O)s 2-(CH 2CH 2CH 2O)s 3-(CH 2CH 2O)s 4-,所述的*-(CH 2CH 2O)s 1-和*-(CH 2CH 2O)s 2-(CH 2CH 2CH2O)s 3-(CH 2CH 2O)s 4-是未被取代的或各自独立地被一个或多个取代基所取代,其中每个取代基独立地选自卤素、C 1-6烷基、C 3-6环烷基和C 1-6烷氧基;s 1选自1-10,优选1-5;s 2选自0-10,优选1-5;s 3选自1-10,优选1-5;s 4选自0-10,优选1-5;星号*表示与所述连接子L结合;
条件是P 1、P 2不同时为羟基或*-(CH 2CH 2O)s 1-;
所述的Pc如权利要求14所述;优选地,其中所述Pc选自抗HER2抗体、抗HER3抗体、抗Claudin18.2抗体和抗CD19抗体;
更优选地,所述的抗HER2抗体包含序列如SEQ ID NO:1所示的轻链,和序列如SEQ ID NO:2所示的重链;所述的抗Claudin18.2抗体包含序列如SEQ ID NO:3所示的轻链,和序列如SEQ ID NO:4所示的重链;所述的抗HER3抗体包含序列如SEQ ID NO:5所示的轻链,和序列如SEQ ID NO:6所示的重链。 - 一种式(DL)所示的化合物或其可药用的盐:其中:R 11为H、氧代基、卤素或烷基;R 13为L a’-L b-L c-L d-:L a’为L b选自-C(O)-CH 2CH 2-C(O)-、-C(O)-(CH 2CH 2) 2-C(O)-、-C(O)-CH 2CH 2-C(O)-NH-(CH 2CH 2) 2-C(O)-、-C(O)-CH 2CH 2-C(O)-NH-(CH 2CH 2O) 2-CH 2-C(O)-、-C(O)-CH 2CH 2-NH-C(O)-(CH 2CH 2O) 4-CH 2CH 2-C(O)-、-CH 2-OC(O)-和-OC(O)-;L c为由2至7个氨基酸残基构成的肽残基,其中所述氨基酸残基是由苯丙氨酸、丙氨酸、脯氨酸、异亮氨酸、甘氨酸、缬氨酸、赖氨酸、瓜氨酸、丝氨酸、谷氨酸或天冬氨酸所形成的残基,所述氨基酸残基是未被取代的或各自独立地被一个或多个取代基所取代,其中每个取代基独立地选自卤素、羟基、氰基、氨基、C 1-6烷基、卤代C 1-6烷基、C 1-6烷氧基和C 3-7环烷基;L d为-NH-R a-CH 2O-C(O)-、-NH-CH 2O-R b-C(O)-或键;R a为苯基或5-6元杂环基,所述苯基和5-6元杂环基是未被取代的或各自独立地被一个或多个取代基所取代,其中每个取代基独立地选自卤素、氧代基、羟基、氰基、氨基、C 1-6烷基、卤代C 1-6烷基和C 1-6烷氧基;R b为C 1-6烷基或C 3-7环烷基,所述C 1-6烷基和C 3-7环烷基是未被取代的或各自独立地被一个或多个取代基所取代,其中每个取代基独立地选自卤素、氧代基、羟基、氰基、氨基、C 1-6烷基、C 3-7环烷基、5-6元杂环基、卤代C 1-6烷基和C 1-6烷氧基;R 14为H、羟基或烷氧基;或者R 13和R 14与相连的原子一起形成亚胺键(N=C);R 15为H或烷基;R 16为H或烷基;R 17为H、卤素或烷基;或者R 15和R 16与其所连接的原子一起成环,或R 16和R 17与其所连接的原子 一起成环;R 18为H或烷基;R 19为烷基或环烷基;或者R 18和R 19与其所连接的原子一起成环;R 20为烷基或环烷基;X’为亚烷基或-(CH 2) m’-X’ 1-(CH 2) n’-;X’ 1为氮原子、氧原子、硫原子、环烷基、杂环基、杂芳基或芳基;所述的环烷基、杂环基、杂芳基或芳基任选被一个或多个取代基所取代,其中每个取代基独立地选自氨基、羟基、羟烷基、烷基和烷氧基;Y’为键、氮原子、氧原子或硫原子;A’为烷基、环烷基、杂环基、芳基或杂芳基,所述的环烷基、杂环基、芳基或杂芳基任选被一个或多个取代基所取代,其中每个取代基独立地选自卤素、羟基、羟烷基、烷基、烷氧基、-C(O)R 21、环烷基、环烷基烷基、卤代烷基、芳基和杂环基;R 21为H、烷基和羟烷基;m'为1,2或3;n’为1,2或3;条件是当X’为亚烷基时,1)R 11为氧代基,或2)R 14为H,或3)R 16和R 17与其所连接的原子一起成环,或4)R 18和R 19与其所连接的原子一起成环,或5)R 19和/或R 20为环烷基;或6)A’不是烷基。
- 根据权利要求21所述的化合物或其可药用的盐,其中R 13和R 14与相连的原子一起形成亚胺键(N=C)。
- 根据权利要求21或22所述的化合物或其可药用的盐,其中:R 13为L a’-L b-L c-L d-:L a’为L b选自-C(O)-CH 2CH 2-C(O)-、-C(O)-(CH 2CH 2) 2-C(O)-、-C(O)-CH 2CH 2-C(O)-NH-(CH 2CH 2) 2-C(O)-、-C(O)-CH 2CH 2-C(O)-NH-(CH 2CH 2O) 2-CH 2-C(O)-、-C(O)-CH 2CH 2-NH-C(O)-(CH 2CH 2O) 4-CH 2CH 2-C(O)-、-CH 2-OC(O)-和-OC(O)-;L c为由2至7个氨基酸残基构成的肽残基,其中所述氨基酸残基是由苯丙氨酸、丙氨酸、脯氨酸、异亮氨酸、甘氨酸、缬氨酸、赖氨酸、瓜氨酸、丝氨酸、 谷氨酸或天冬氨酸所形成的残基,所述氨基酸残基是未被取代的或各自独立地被一个或多个取代基所取代,其中每个取代基独立地选自卤素、羟基、氰基、氨基、C 1-6烷基、卤代C 1-6烷基、C 1-6烷氧基和C 3-7环烷基;L d为-NH-R a-CH 2O-C(O)-、-NH-CH 2O-R b-C(O)-或键;R a为苯基或5-6元杂环基,所述苯基和5-6元杂环基是未被取代的或各自独立地被一个或多个取代基所取代,其中每个取代基独立地选自卤素、氧代基、羟基、氰基、氨基、C 1-6烷基、卤代C 1-6烷基和C 1-6烷氧基;R b为C 1-6烷基或C 3-7环烷基,所述C 1-6烷基和C 3-7环烷基是未被取代的或各自独立地被一个或多个取代基所取代,其中每个取代基独立地选自卤素、氧代基、羟基、氰基、氨基、C 1-6烷基、C 3-7环烷基、5-6元杂环基、卤代C 1-6烷基和C 1-6烷氧基。
- 根据权利要求21所述的化合物或其可药用的盐,其中R 14为H或羟基;优选地,R 14为羟基。
- 根据权利要求21至24中任一项所述的化合物或其可药用的盐,其中所述R 11为H或氧代基;优选地,R 11为H。
- 根据权利要求21至25中任一项所述的化合物或其可药用的盐,其中所述R 12为H或C 1-6烷基;优选地,R 12为H。
- 根据权利要求21至27中任一项所述的化合物或其可药用的盐,其中:R 11为H或烷基;优选地,R 11为H或C 1-6烷基;R 15和R 16与其所连接的原子一起形成3-6元碳环;R 17为H;R 18为H;R 19是烷基;优选地,R 19为C 1-6烷基;R 20是烷基;优选地,R 20为C 1-6烷基;X’为亚烷基;优选地,X’为C 1-6亚烷基;更优选地,X’为亚戊基;Y’选自键、氮原子、氧原子或硫原子;优选地,Y’为键或硫原子;更优选地,Y’为键;A’为环烷基、杂环基、芳基或杂芳基,所述的环烷基、杂环基、芳基或杂芳基任选被一个或多个取代基所取代,其中每个取代基独立地选自卤素、羟基、羟烷基、烷基、烷氧基、-C(O)R 21、环烷基、环烷基烷基、卤代烷基、芳基和杂环基;优选地,A’选自C 3-6环烷基、5至6元杂环基、苯基或5至6元杂芳基,所述的C 3-6环烷基、5至6元杂环基、苯基或5至6元杂芳基任选被一个或多个取代基所取代,其中每个取代基独立地选自C 1-6羟烷基、C 1-6烷基、C 3-6环烷基C 1-6烷基、卤代C 1-6烷基和-C(O)R 21;R 21选自H、烷基和羟烷基;优选地,R 21为C 1-6烷基或C 1-6羟烷基。
- 根据权利要求21至27中任一项所述的化合物或其可药用的盐,其中:R 11为H或烷基;优选地,R 11为H或C 1-6烷基;R 15和R 16与其所连接的原子一起形成3-6元碳环;R 17为H;R 18为H;R 19是烷基;优选地,R 19为C 1-6烷基;R 20是烷基;优选地,R 20为C 1-6烷基;X’为-(CH 2) m’-X’ 1-(CH 2) n’-;X’ 1为氮原子、氧原子、硫原子、环烷基、杂芳基或芳基;所述的环烷基、杂芳基或芳基任选被一个或多个取代基所取代,其中每个取代基独立地选自氨基、羟基、羟烷基、烷基和烷氧基;优选地,X’ 1为氧原子、C 3-6环烷基、吡啶基或苯基;所述的C 3-6环烷基、吡啶基或苯基任选被一个或多个氨基或C 1-6烷基所取代;Y’为氧原子;A’为烷基;优选地A’为C 1-6烷基;m'选自1,2或3;n’选自1,2或3。
- 根据权利要求21至27中任一项所述的化合物或其可药用的盐,其中:R 11为H或烷基;优选地,R 11为H或C 1-6烷基;R 15和R 16与其所连接的原子一起形成3-6元碳环;R 17为H;R 18为H或烷基;优选地,R 18为H或C 1-6烷基;R 19为烷基或环烷基;优选地,R 19为C 1-6烷基或C 1-6羟烷基;或者R 18和R 19与其所连接的原子一起成环;优选地,R 18和R 19与其所连接的原子一起形成3-6元碳环;R 20为烷基或环烷基;优选地,R 20为C 1-6烷基或C 1-6羟烷基;X’为亚烷基;优选地,X’为C 1-6亚烷基;更优选地,X’为亚戊基;Y’为氧原子;A’为烷基;优选地A’为C 1-6烷基;条件是,R 19和R 20不同时为烷基。
- 根据权利要求21至27中任一项所述的化合物或其可药用的盐,其中:R 11为H或C 1-6烷基;优选地,R 11为H;R 15为H;R 16和R 17与其所连接的原子一起形成3-6元碳环;R 18为H;R 19是烷基;优选地,R 19为C 1-6烷基;R 20是烷基;优选地,R 20为C 1-6烷基;X’为亚烷基;优选地,X’为C 1-6亚烷基;更优选地,X’为亚戊基;Y’为氧原子;A’为烷基;优选地A’为C 1-6烷基。
- 一种药物组合物,其含有治疗有效量的根据权利要求1至20中任一项所述的抗体-药物偶联物或其可药用的盐,或根据权利要求21至32中任一项所述的式(DL)所示化合物或其可药用的盐,以及药学上可接受的载体、稀释剂或赋形剂。
- 根据权利要求1至20中任一项所述的抗体-药物偶联物或其可药用的盐,或根据权利要求21至32中任一项所述的式(DL)所示化合物或其可药用的盐,或根据权利要求33所述的药物组合物用作药物。
- 根据权利要求1至20中任一项所述的抗体-药物偶联物或其可药用的盐,或根据权利要求21至32中任一项所述的式(DL)所示化合物或其可药用的盐,或根据权利要求33所述的药物组合物在制备用于治疗肿瘤的药物中的用途;优选地,所述肿瘤为卵巢癌、肺癌、胃癌、子宫内膜癌、睾丸癌、宫颈癌、胎盘绒毛膜癌、肾癌、尿路上皮癌、大肠癌、前列腺癌、多形性神经胶质母细胞瘤、脑肿瘤、胰腺癌、乳腺癌、黑色素瘤、肝癌、膀胱癌或食道癌。
- 一种式(OLS)所示的二糖化合物:P 3、P 4各自独立地选自羟基、N 3-(CH 2CH 2O)s 1-和N 3-(CH 2CH 2O)s 2-(CH 2CH 2CH 2O)s 3-(CH 2CH 2O)s 4-,所述的N 3-(CH 2CH 2O)s 1-和N 3-(CH 2CH 2O)s 2-(CH 2CH 2CH 2O)s 3-(CH 2CH 2O)s 4-是未被取代的或各自独立地被一个或多个取代基所取代,其中每个取代基独立地选自卤素、C 1-6烷基、C 3-6环烷基和C 1-6烷氧基;s 1选自1-10,优选1-5;s 2选自0-10,优选1-5;s 3选自1-10,优选1-5;s 4选自0-10,优选1-5;条件是,P 3、P 4不同时为羟基或N 3-(CH 2CH 2O)s 1-;优选地,式(OLS)所示的二糖化合物选自:
- 一种糖分子,其为:N 3-(CH 2CH 2O)q-CH 2CH 2-NH-NeuAcα2-6Galβ1-4GlcNAcβ1-2Manα1-6Manβ1-4GlcN-OxaNeuAcα2-6Galβ1-4GlcNAcβ1-2Manα1-3或NeuAcα2-6Galβ1-4GlcNAcβ1-2Manα1-6Manβ1-4GlcN-OxaN 3-(CH 2CH 2O)q-CH 2CH 2-NH-NeuAcα2-6Galβ1-4GlcNAcβ1-2Manα1-3式中,q为0-20;优选地,q为1-10;更优选地,q为2或3;其中,Oxa代表噁唑啉环。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022353890A AU2022353890A1 (en) | 2021-09-30 | 2022-09-30 | Pyrrolo benzodiazepine derivative, and conjugate, preparation method and use thereof |
CA3232764A CA3232764A1 (en) | 2021-09-30 | 2022-09-30 | Pyrrolo benzodiazepine derivative, and conjugate, preparation method and use thereof |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111164628.1 | 2021-09-30 | ||
CN202111164628 | 2021-09-30 | ||
CN202111399183 | 2021-11-19 | ||
CN202111399183.5 | 2021-11-19 | ||
CN202210363759.0 | 2022-04-07 | ||
CN202210363759 | 2022-04-07 | ||
CN202210836645 | 2022-07-15 | ||
CN202210836645.3 | 2022-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023051814A1 true WO2023051814A1 (zh) | 2023-04-06 |
Family
ID=85781380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/123462 WO2023051814A1 (zh) | 2021-09-30 | 2022-09-30 | 吡咯并苯并二氮杂卓类衍生物及其偶联物、其制备方法及其应用 |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU2022353890A1 (zh) |
CA (1) | CA3232764A1 (zh) |
TW (1) | TW202330608A (zh) |
WO (1) | WO2023051814A1 (zh) |
Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US20050238649A1 (en) | 2003-11-06 | 2005-10-27 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
WO2006134341A1 (en) | 2005-06-13 | 2006-12-21 | Merck Sharp & Dohme Limited | Therapeutic agents |
EP1921074A1 (en) | 2005-08-31 | 2008-05-14 | Astellas Pharma Inc. | Thiazole derivative |
WO2013053872A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
US20130210798A1 (en) | 2010-10-28 | 2013-08-15 | John Q. Tan | Soluble guanylate cyclase activators |
WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014057119A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
CN104098481A (zh) | 2013-04-10 | 2014-10-15 | 浙江九洲药物科技有限公司 | 一种沙格列汀中间体的制备方法 |
CN104395312A (zh) | 2013-06-21 | 2015-03-04 | 四川海思科制药有限公司 | 4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物、其制备方法以及应用 |
WO2015052321A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
CN105246894A (zh) * | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
WO2016149546A1 (en) | 2015-03-19 | 2016-09-22 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
WO2016166307A1 (en) | 2015-04-15 | 2016-10-20 | Van Berkel Patricius Hendrikus Cornelis | Site-specific antibody-drug conjugates |
US20160361436A1 (en) | 2015-01-09 | 2016-12-15 | Isis Innovation Limited | Antibody conjugates and methods of making the antibody conjugates |
WO2017004026A1 (en) | 2015-06-29 | 2017-01-05 | Immunogen, Inc. | Anti-cd 123 antibodies and conjugates and derivatives thereof |
CN109071502A (zh) * | 2016-01-26 | 2018-12-21 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂* |
CN109180681A (zh) | 2017-08-18 | 2019-01-11 | 四川百利药业有限责任公司 | 一种dna毒性二聚体化合物 |
WO2019046859A1 (en) | 2017-09-02 | 2019-03-07 | Abbvie Inc. | ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF |
WO2019065964A1 (ja) | 2017-09-29 | 2019-04-04 | 第一三共株式会社 | 抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
KR20190109007A (ko) | 2018-03-16 | 2019-09-25 | 재단법인 대구경북첨단의료산업진흥재단 | TGase 2 억제제로서의 퀴놀린-5,8-디온 유도체 및 이를 포함하는 약제학적 조성물 |
WO2020002487A1 (en) | 2018-06-29 | 2020-01-02 | F. Hoffmann-La Roche Ag | Compounds |
WO2020006722A1 (en) | 2018-07-05 | 2020-01-09 | Hangzhou Dac Biotech Co., Ltd | Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates |
WO2020063676A1 (zh) | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
WO2020196475A1 (ja) * | 2019-03-25 | 2020-10-01 | 第一三共株式会社 | 抗her2抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
WO2020196474A1 (ja) * | 2019-03-25 | 2020-10-01 | 第一三共株式会社 | 抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
WO2020196712A1 (ja) * | 2019-03-27 | 2020-10-01 | 第一三共株式会社 | 抗体-ピロロベンゾジアゼピン誘導体コンジュゲートとparp阻害剤の組み合わせ |
US10851174B2 (en) | 2011-03-03 | 2020-12-01 | University Of Maryland, Baltimore | Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof |
CN112110918A (zh) | 2019-06-21 | 2020-12-22 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物,其制法与医药上的用途 |
WO2021115426A1 (zh) | 2019-12-12 | 2021-06-17 | 江苏恒瑞医药股份有限公司 | 抗密蛋白抗体药物偶联物及其医药用途 |
CN113166764A (zh) | 2018-11-14 | 2021-07-23 | 第一三共株式会社 | 抗cdh6抗体-吡咯并苯并二氮杂环庚三烯衍生物缀合物 |
CN113260621A (zh) * | 2019-01-03 | 2021-08-13 | 乐高化学生物科学股份有限公司 | 安全性得到提高的吡咯并苯并二氮杂二聚体化合物及其用途 |
WO2021193951A1 (ja) * | 2020-03-26 | 2021-09-30 | 公益財団法人野口研究所 | ポリエチレングリコール鎖を有する糖化合物、及び抗体薬物複合体の前駆体 |
CN114949236A (zh) * | 2021-02-22 | 2022-08-30 | 中国科学院上海药物研究所 | 二糖连接子、二糖-小分子药物偶联物以及糖链定点抗体-药物偶联物,其制备方法及用途 |
-
2022
- 2022-09-30 TW TW111137361A patent/TW202330608A/zh unknown
- 2022-09-30 WO PCT/CN2022/123462 patent/WO2023051814A1/zh active Application Filing
- 2022-09-30 AU AU2022353890A patent/AU2022353890A1/en active Pending
- 2022-09-30 CA CA3232764A patent/CA3232764A1/en active Pending
Patent Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US20050238649A1 (en) | 2003-11-06 | 2005-10-27 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
WO2006134341A1 (en) | 2005-06-13 | 2006-12-21 | Merck Sharp & Dohme Limited | Therapeutic agents |
EP1921074A1 (en) | 2005-08-31 | 2008-05-14 | Astellas Pharma Inc. | Thiazole derivative |
US20130210798A1 (en) | 2010-10-28 | 2013-08-15 | John Q. Tan | Soluble guanylate cyclase activators |
US10851174B2 (en) | 2011-03-03 | 2020-12-01 | University Of Maryland, Baltimore | Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof |
WO2013053872A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014057119A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
CN105246894A (zh) * | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
CN104098481A (zh) | 2013-04-10 | 2014-10-15 | 浙江九洲药物科技有限公司 | 一种沙格列汀中间体的制备方法 |
CN104395312A (zh) | 2013-06-21 | 2015-03-04 | 四川海思科制药有限公司 | 4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物、其制备方法以及应用 |
WO2015052321A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
US20160361436A1 (en) | 2015-01-09 | 2016-12-15 | Isis Innovation Limited | Antibody conjugates and methods of making the antibody conjugates |
WO2016149546A1 (en) | 2015-03-19 | 2016-09-22 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
WO2016166307A1 (en) | 2015-04-15 | 2016-10-20 | Van Berkel Patricius Hendrikus Cornelis | Site-specific antibody-drug conjugates |
WO2017004026A1 (en) | 2015-06-29 | 2017-01-05 | Immunogen, Inc. | Anti-cd 123 antibodies and conjugates and derivatives thereof |
CN109071502A (zh) * | 2016-01-26 | 2018-12-21 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂* |
CN109180681A (zh) | 2017-08-18 | 2019-01-11 | 四川百利药业有限责任公司 | 一种dna毒性二聚体化合物 |
WO2019046859A1 (en) | 2017-09-02 | 2019-03-07 | Abbvie Inc. | ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF |
WO2019065964A1 (ja) | 2017-09-29 | 2019-04-04 | 第一三共株式会社 | 抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
CN111164208A (zh) | 2017-09-29 | 2020-05-15 | 第一三共株式会社 | 抗体-吡咯并苯并二氮杂卓衍生物偶联物 |
KR20190109007A (ko) | 2018-03-16 | 2019-09-25 | 재단법인 대구경북첨단의료산업진흥재단 | TGase 2 억제제로서의 퀴놀린-5,8-디온 유도체 및 이를 포함하는 약제학적 조성물 |
WO2020002487A1 (en) | 2018-06-29 | 2020-01-02 | F. Hoffmann-La Roche Ag | Compounds |
WO2020006722A1 (en) | 2018-07-05 | 2020-01-09 | Hangzhou Dac Biotech Co., Ltd | Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates |
WO2020063676A1 (zh) | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
CN113166764A (zh) | 2018-11-14 | 2021-07-23 | 第一三共株式会社 | 抗cdh6抗体-吡咯并苯并二氮杂环庚三烯衍生物缀合物 |
CN113260621A (zh) * | 2019-01-03 | 2021-08-13 | 乐高化学生物科学股份有限公司 | 安全性得到提高的吡咯并苯并二氮杂二聚体化合物及其用途 |
WO2020196474A1 (ja) * | 2019-03-25 | 2020-10-01 | 第一三共株式会社 | 抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
WO2020196475A1 (ja) * | 2019-03-25 | 2020-10-01 | 第一三共株式会社 | 抗her2抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
WO2020196712A1 (ja) * | 2019-03-27 | 2020-10-01 | 第一三共株式会社 | 抗体-ピロロベンゾジアゼピン誘導体コンジュゲートとparp阻害剤の組み合わせ |
CN112110918A (zh) | 2019-06-21 | 2020-12-22 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物,其制法与医药上的用途 |
WO2021115426A1 (zh) | 2019-12-12 | 2021-06-17 | 江苏恒瑞医药股份有限公司 | 抗密蛋白抗体药物偶联物及其医药用途 |
WO2021193951A1 (ja) * | 2020-03-26 | 2021-09-30 | 公益財団法人野口研究所 | ポリエチレングリコール鎖を有する糖化合物、及び抗体薬物複合体の前駆体 |
CN114949236A (zh) * | 2021-02-22 | 2022-08-30 | 中国科学院上海药物研究所 | 二糖连接子、二糖-小分子药物偶联物以及糖链定点抗体-药物偶联物,其制备方法及用途 |
Non-Patent Citations (13)
Title |
---|
ACS CHEMICAL BIOLOGY, vol. 7, 2012, pages 110 |
ACS MEDICINAL CHEMISTRY LETTERS, vol. 7, 2016, pages 1005 |
ANGEW. CHEM. INT. ED., vol. 55, 2016, pages 2361 - 2367 |
BIOCONJUGATE CHEMISTRY, vol. 26, 2015, pages 2233 |
BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 20, no. 14, 2012, pages 2982 - 2991 |
BIOTECHNOL. PROG., vol. 28, 2012, pages 608 - 622 |
CHARI ET AL., CANCER RESEARCH, vol. 52, 1992, pages 127 - 131 |
EDELMAN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 63, no. 1, 15 May 1969 (1969-05-15), pages 78 - 85 |
HELVETICA CHIMICA ACTA, vol. 95, 2012, pages 1928 - 1936 |
JOURNAL OF CARBOHYDRATE CHEMISTRY, vol. 36, 2017, pages 336 - 346 |
JOURNAL OF THE AMERICAN CHEMISTRY SOCIETY, vol. 130, 2008, pages 13790 - 13803 |
ORGANIC LETTERS, vol. 9, 2007, pages 3797 - 3800 |
SANGLIER-CIANFERANI, S., ANAL. CHEM., vol. 85, 2013, pages 715 - 736 |
Also Published As
Publication number | Publication date |
---|---|
CA3232764A1 (en) | 2023-04-06 |
AU2022353890A1 (en) | 2024-04-04 |
TW202330608A (zh) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI826543B (zh) | 依喜替康類似物的配體-藥物偶聯物、其製備方法及其應用 | |
TWI820044B (zh) | 抗體-吡咯并苯二氮呯衍生物複合體 | |
CN114025844B (zh) | 蛋白酪氨酸磷酸酶抑制剂及其使用方法 | |
CN109790171B (zh) | 吡咯并苯并二氮杂二聚物前体及其配体-连接体缀合化合物 | |
JP6895254B2 (ja) | ペプチド模倣化合物及びその抗体−薬物コンジュゲート | |
WO2022170971A1 (zh) | 生物活性物偶联物及其制备方法和用途 | |
TW201512174A (zh) | 細胞增生抑制劑及其結合物 | |
WO2021190602A1 (zh) | 一种抗体药物偶联物的制备方法 | |
JP2023545581A (ja) | カンプトテシン系誘導体及びそのリガンド-薬物複合体 | |
TWI716976B (zh) | 高活性sting蛋白激動劑 | |
CN111925367A (zh) | 稠环类衍生物抑制剂、其制备方法和应用 | |
CN106243127B (zh) | 抗体药物偶联物、中间体、制备方法、药物组合物及应用 | |
CN114163444A (zh) | 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用 | |
WO2019141153A1 (zh) | 吲哚胺2,3-双加氧酶抑制剂及其用途 | |
WO2023051814A1 (zh) | 吡咯并苯并二氮杂卓类衍生物及其偶联物、其制备方法及其应用 | |
EP4317144A1 (en) | Heterocycle substituted ketone derivative, and composition and medicinal use thereof | |
CN115403584A (zh) | 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用 | |
CN113880833A (zh) | 联苯多环类衍生物抑制剂、其制备方法和应用 | |
CN107660208B (zh) | 包含cti药效团的双功能细胞毒性剂 | |
CN116785449A (zh) | 苯并吡咯并杂环类化合物及其偶联物、其制备方法及其应用 | |
WO2023232142A1 (zh) | 一种药物化合物及其用途 | |
WO2023221975A1 (zh) | 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 | |
TW202400788A (zh) | 用於靶向遞送治療劑的雙環雜環及其配體 | |
WO2024022444A1 (zh) | 稠环类化合物、其制备方法及其在医药上的应用 | |
CN115536576A (zh) | 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22875194 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3232764 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022353890 Country of ref document: AU Ref document number: AU2022353890 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022353890 Country of ref document: AU Date of ref document: 20220930 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024006314 Country of ref document: BR |